SG11201501955VA - Drug-protein conjugates - Google Patents

Drug-protein conjugates

Info

Publication number
SG11201501955VA
SG11201501955VA SG11201501955VA SG11201501955VA SG11201501955VA SG 11201501955V A SG11201501955V A SG 11201501955VA SG 11201501955V A SG11201501955V A SG 11201501955VA SG 11201501955V A SG11201501955V A SG 11201501955VA SG 11201501955V A SG11201501955V A SG 11201501955VA
Authority
SG
Singapore
Prior art keywords
drug
protein conjugates
conjugates
protein
Prior art date
Application number
SG11201501955VA
Other languages
English (en)
Inventor
John Burt
Antony Godwin
Mark Frigerio
George Badescu
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of SG11201501955VA publication Critical patent/SG11201501955VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201501955VA 2012-10-24 2013-10-11 Drug-protein conjugates SG11201501955VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717743P 2012-10-24 2012-10-24
PCT/GB2013/052662 WO2014064424A1 (en) 2012-10-24 2013-10-11 Drug-protein conjugates

Publications (1)

Publication Number Publication Date
SG11201501955VA true SG11201501955VA (en) 2015-04-29

Family

ID=49488609

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501955VA SG11201501955VA (en) 2012-10-24 2013-10-11 Drug-protein conjugates

Country Status (20)

Country Link
US (1) US20150283259A1 (ja)
EP (1) EP2911696B1 (ja)
JP (1) JP6328649B2 (ja)
KR (1) KR20150085808A (ja)
CN (1) CN104755106B (ja)
AU (1) AU2013336410B2 (ja)
BR (1) BR112015008311A2 (ja)
CA (1) CA2884359A1 (ja)
DK (1) DK2911696T3 (ja)
ES (1) ES2652513T3 (ja)
HK (1) HK1208186A1 (ja)
HU (1) HUE037604T2 (ja)
IL (1) IL237673A0 (ja)
IN (1) IN2015DN02577A (ja)
MX (1) MX2015005124A (ja)
NO (1) NO2789793T3 (ja)
RU (1) RU2015119557A (ja)
SG (1) SG11201501955VA (ja)
WO (1) WO2014064424A1 (ja)
ZA (1) ZA201501996B (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105188766B (zh) 2013-03-15 2019-07-12 瑞泽恩制药公司 生物活性分子、其偶联物及治疗用途
WO2014194030A2 (en) * 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP3038624A1 (en) 2013-08-26 2016-07-06 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
US10406198B2 (en) * 2014-05-23 2019-09-10 Novartis Ag Methods for making conjugates from disulfide-containing proteins
WO2015187596A2 (en) * 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
GB2531715A (en) * 2014-10-24 2016-05-04 Polytherics Ltd Novel drug conjugates
KR20230158134A (ko) 2014-10-14 2023-11-17 폴리테릭스 리미티드 Peg의 일부를 포함하는 이탈기를 포함하는 시약을 사용한, 펩티드 또는 단백질의 접합방법
JP6612860B2 (ja) * 2014-10-24 2019-11-27 ポリセリックス・リミテッド コンジュゲート及びコンジュゲート試薬
EP3319936A4 (en) 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3331569A1 (en) * 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
MY198605A (en) 2016-01-25 2023-09-08 Regeneron Pharma Maytansinoid derivatives conjugates thereof, and methods of use
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
EP3442595A1 (en) 2016-04-14 2019-02-20 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
JP7179719B2 (ja) 2016-06-06 2022-11-29 ポリセリックス・リミテッド 抗体、その使用及びそのコンジュゲート
GB201615725D0 (en) * 2016-09-15 2016-11-02 Polytherics Ltd Novel cytotoxic agents and conjugates thereof
JP7138350B2 (ja) 2016-11-14 2022-09-16 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. 共役連結体、該連結体を含有する細胞結合分子-薬物共役体、並びに該共役体及び連結体の使用及び製造方法
US10864279B2 (en) 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
EP3991752A4 (en) 2019-06-29 2023-03-29 Hangzhou Dac Biotech Co., Ltd CELL BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND METHOD OF PREPARATION THEREOF
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
AU2021337687A1 (en) 2020-09-04 2023-03-23 Novarock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
CA3213295A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
CN117147824A (zh) * 2022-05-29 2023-12-01 菲鹏生物股份有限公司 一种抗体缀合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
SG10201701737XA (en) * 2003-11-06 2017-04-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
NZ566982A (en) * 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
JP5727786B2 (ja) * 2007-10-19 2015-06-03 シアトル ジェネティクス,インコーポレーテッド Cd19結合性物質およびその使用
BRPI0911442A2 (pt) * 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
EP2403538B1 (en) 2009-03-04 2017-10-04 Polytherics Limited Conjugated proteins and peptides
AR078471A1 (es) * 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
CA2876365A1 (en) * 2012-06-19 2013-12-27 Polytherics Limited Novel process for preparation of antibody conjugates and novel antibody conjugates

Also Published As

Publication number Publication date
BR112015008311A2 (pt) 2017-07-04
ES2652513T3 (es) 2018-02-02
CA2884359A1 (en) 2014-05-01
MX2015005124A (es) 2015-10-29
CN104755106A (zh) 2015-07-01
NO2789793T3 (ja) 2018-01-27
AU2013336410B2 (en) 2017-08-03
WO2014064424A1 (en) 2014-05-01
ZA201501996B (en) 2016-01-27
EP2911696A1 (en) 2015-09-02
HUE037604T2 (hu) 2018-09-28
RU2015119557A (ru) 2016-12-20
HK1208186A1 (en) 2016-02-26
CN104755106B (zh) 2018-03-13
EP2911696B1 (en) 2017-09-20
IL237673A0 (en) 2015-04-30
IN2015DN02577A (ja) 2015-09-11
KR20150085808A (ko) 2015-07-24
DK2911696T3 (en) 2018-01-08
JP2015536329A (ja) 2015-12-21
US20150283259A1 (en) 2015-10-08
AU2013336410A1 (en) 2015-04-09
JP6328649B2 (ja) 2018-05-23

Similar Documents

Publication Publication Date Title
HUS2300020I1 (hu) Pirrolobenzodiazepin-antitest konjugátumok
HRP20181646T1 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
IL263973B (en) Protein-polymer-drug conjugates
ZA201501996B (en) Drug-protein conjugates
IL237672B (en) Drug-protein conjugates
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
ZA201502267B (en) Pyrrolobenzodiazepine-anti-her2 antibody conjugates
LT2906251T (lt) Pirolobenzodiazepino-anti-cd22 antikūno konjugatai
HK1196257A1 (zh) -抗體結合物
IL228404A0 (en) Antibody-drug captures
EP2920167A4 (en) HYDRAZINYL-INDOLES AND CONJUGATED COMPOUNDS
HK1204555A1 (en) Conjugation reagents